Sarepta (SPRT) volatility elevated into announcing FDA requesting more data up into FDA review of eteplirsen

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. META
5. TSLA
6. ISRG
7. SMCI
8. GOOGL
9. RTX
10. S

Go back to Sarepta (SPRT) volatility elevated into announcing FDA requesting more data up into FDA review of eteplirsen

Piper Jaffray Remains Negative on Sarepta (SRPT), 'Unable to Handicap Chances for AA'

June 7, 2016 9:08 AM EDT

Piper Jaffray analyst Edward Tenthoff maintained an Underperform rating and $6 price target on Sarepta Therapeutic (NASDAQ: SRPT) after the FDA requested Sarepta provide additional dystrophin data from the ongoing confirmatory PROMOVI trial of eteplirsen. Sarepta plans to submit western blot data from biopsy... More

Sarepta (SRPT): Accelerated Approval Seen Pending Dystrophin Data Analysis - Oppenheimer

June 7, 2016 6:49 AM EDT

Oppenheimer analyst, Christopher Marai, reiterated his Outperform rating after Sarepta Therapeutic (NASDAQ: SRPT) announced the FDA has requested dystrophin data (n=13) from ongoing PROMOVI confirmatory trial of eteplirsen, prior to making an approval decision. SRPT indicated to us biopsies have been completed but... More